DILACOR XR Drug Patent Profile
✉ Email this page to a colleague
When do Dilacor Xr patents expire, and when can generic versions of Dilacor Xr launch?
Dilacor Xr is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in DILACOR XR is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dilacor Xr
A generic version of DILACOR XR was approved as diltiazem hydrochloride by TEVA on May 31st, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DILACOR XR?
- What are the global sales for DILACOR XR?
- What is Average Wholesale Price for DILACOR XR?
Summary for DILACOR XR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 32 |
| Clinical Trials: | 1 |
| Patent Applications: | 72 |
| DailyMed Link: | DILACOR XR at DailyMed |
Recent Clinical Trials for DILACOR XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assiut University | Early Phase 1 |
US Patents and Regulatory Information for DILACOR XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-001 | May 29, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-002 | May 29, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-003 | May 29, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DILACOR XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-002 | May 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-001 | May 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-002 | May 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-003 | May 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-001 | May 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Allergan | DILACOR XR | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020092-003 | May 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DILACOR XR
See the table below for patents covering DILACOR XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 218596 | SYSTEM FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES | ⤷ Sign Up |
| Canada | 2031393 | COMPRIMES A LIBERATION PROGRESSIVE DE SUBSTANCES ACTIVES (TABLETS WITH CONTROLLED-RATE RELEASE OF ACTIVE SUBSTANCES) | ⤷ Sign Up |
| Spain | 2085316 | ⤷ Sign Up | |
| Greece | 3001141 | ⤷ Sign Up | |
| Italy | 8922694 | ⤷ Sign Up | |
| Italy | 8523321 | ⤷ Sign Up | |
| Japan | H06172162 | TABLET PROVIDED WITH RELEASE OF ACTIVE SUBSTANCE WITH CONTROLLED SPEED | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
